Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke

Bruce Ovbiagele, Eric E. Smith, Lee H. Schwamm, Maria V. Grau-Sepulveda, Jeffrey L. Saver, Deepak L. Bhatt, Adrian F. Hernandez, Eric D. Peterson, Gregg C. Fonarow

Research output: Contribution to journalArticlepeer-review

Abstract

Background-The safety of intravenous thrombolysis in ischemic stroke (IS) patients with chronic kidney disease (CKD) is uncertain. We assessed whether CKD is associated with bleeding complications after intravenous tissue-type plasminogen activator administration to patients with IS. Methods and Results-Data were analyzed from 44 410 patients with IS treated with intravenous tissue-type plasminogen activator in the Get With The Guidelines-Stroke Program. Glomerular filtration rate based on admission serum creatinine was categorized as dichotomous (presence of CKD as <60) or as distinct categories: normal (≥90), mild (≥60-<90), moderate (≥30-< 60), severe (≥15-<30), and kidney failure (<15 or dialysis). Primary outcomes evaluated were symptomatic intracranial hemorrhage and serious systemic hemorrhage; secondary outcomes were in-hospital mortality, independent functional status. There were 15 191 of 44 410 (34%) intravenous tissue-type plasminogen activator-treated IS patients with CKD. Presence of CKD (versus no CKD) was not associated with risk-adjusted symptomatic intracranial hemorrhage (adjusted odds ratio, 1.0; 95% confidence interval: 0.91-1.10) or serious systemic hemorrhage (adjusted odds ratio, 0.97; 95% confidence interval: 0.80-1.18) and did not significantly vary by kidney dysfunction stage for either of these primary end points in multivariable analyses. Compared with patients with normal kidney function, those with CKD were more likely to die in the hospital (adjusted odds ratio, 1.22; 95% confidence interval: 1.14-1.32) and have an unfavorable discharge functional status (adjusted odds ratio, 1.13; 95% CI: 1.07-1.19). Conclusions-Presence of CKD among patients with IS treated with intravenous tissue-type plasminogen activator is associated with higher unadjusted odds of symptomatic intracranial hemorrhage or serious systemic hemorrhage, but this is explained by non-CKD related factors.

Original languageEnglish (US)
Pages (from-to)929-935
Number of pages7
JournalCirculation: Cardiovascular Quality and Outcomes
Volume7
Issue number6
DOIs
StatePublished - Nov 1 2014
Externally publishedYes

Keywords

  • Chronic
  • Glomerular filtration rate
  • Hemorrhage
  • Prognosis
  • Renal Insufficiency

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Chronic kidney disease and bleeding complications after intravenous thrombolytic therapy for acute ischemic stroke'. Together they form a unique fingerprint.

Cite this